Navigation Links
XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
Date:12/20/2007

VENICE, Fla., Aug. 10 /PRNewswire/ -- XCPT, LLC has entered into a representation agreement with Lifecore Biomedical, Inc. to market its products to dentists throughout the world.

XCPT's software is a highly graphic, face-to-face, patient consultation and engagement method recognizing the importance of visual learning during treatment planning. With XCPT, the patient is involved in every step of the dental treatment process as the clinician uses the patient's own x-rays, CT scans and/or photographs to communicate treatment options and solutions. "XCPT's software helps patients decide what is best for them in a trusting, open environment," says Dr. Steven J. Feldman, CEO of XCPT. "With its use, we're seeing doctors gain productivity and increased case acceptance by simply showing the patient what they see."

The signing of the agreement reinforces XCPT's ongoing strategy to be the patient engagement and communication software of choice for the leading implant manufacturers, dental schools and dental practices throughout the country. The agreement with Lifecore marks the third dental implant company and seventh company overall which has begun to incorporate XCPT as a practice- building tool throughout their salesforce.

"We're honored and pleased to have forged this agreement with Lifecore," said Dr. Feldman. "From the time of our first meeting with Lifecore, we were excited about the prospects of becoming integrated into their sales and education curriculum. We see the natural fit between our software's communication capabilities and Lifecore's ability to market implants worldwide."

Speaking on behalf of Lifecore Dental, a Division of Lifecore Biomedical, John DeAngelo, Marketing Portfolio Manager, said, "There are four steps to pre-surgical treatment planning: 1. patient expectations, 2. prosthetic options, 3. biomechanical principles and 4. the team approach which involves the surgeon, restoring dentist and the laboratory. XCPT provides the clinician and their patients a predictable environment for planning all aspects of the implant reconstruction. It allows the doctor to make the important decisions on treatment planning and allows for clear communication between the treatment team and the patient. Finally, it provides patient confidence knowing that a team worked together for an optimal outcome."

To reach a Lifecore sales representative in your area, call 1-800-752- 2663.

For more information or to download the FREE full version 30-day trial, call XCPT at 866.927.9278 or visit http://www.xcpt.com

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LCBM) in business over 40 years, develops, manufactures and markets biomaterials and medical devices for use in various surgical markets through two divisions, the Dental Division and the Hyaluronan Division. The Dental Division conducts its dental surgery business through direct sales and marketing in the United States, France, Germany, Italy and Sweden and through distributors in 49 other countries. The Hyaluronan Division conducts its business through OEM and contract manufacturing alliances in the ophthalmic, orthopedic and veterinary surgical fields.

General Corporate Information is available on the internet at http://www.lifecore.com

About XCPT, LLC

XCPT's Patient Engagement and Communication software was developed to provide an innovative communication method for patients and their healthcare professionals. With its adoption, communication becomes clearer for dental teams in their relationships with patients, their team members, and their referral networks.


'/>"/>
SOURCE XCPT, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: